Nanobiotix S.A. (NASDAQ:NBTX) is one of the best small cap stocks to buy for the long term.
Nanobiotix S.A. (NASDAQ:NBTX) announced on June 2 an update on operational progress and reported financial results for the first quarter of 2026
The company reported €42.1 million in cash and cash equivalents as of March 31, 2026, adding that it is expected to be sufficient to meet its working capital requirements for operations into 2029, which is consistent with the company’s currently contemplated cash burn rate. It also reported the completion of a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, which includes issuance of pre-funded warrants to accelerate the development of Nanobiotix’s (NASDAQ:NBTX) other platforms. Furthermore, the company presented new data from Part 1 of the J&J-sponsored Phase 2 CONVERGE study at the 2026 annual European Society for Radiotherapy and Oncology, which was evaluating JNJ-1900 for patients with Stage 3 inoperable non-small cell lung cancer.
Nanobiotix S.A. (NASDAQ:NBTX) also announced the FDA acceptance of a “protocol amendment to ongoing pivotal J&J sponsored NANORAY-312 study eliminating the previously planned interim analysis and modifying the final analysis to include fewer events and to be conducted sooner”. Nanobiotix S.A. (NASDAQ:NBTX) is a late-stage biotechnology company that develops therapeutic approaches to treat cancer. The company’s technologies include NanoXray, which improves the efficacy of radiation therapy against tumor cells.